Sort   by:  
 Page size 
UnknownIgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WM.
Not available
S-EPMC8602933 | biostudies-literature
UnknownDevelopment of hyperdiploidy starts at an early age and takes a decade to complete.
Not available
S-EPMC12782975 | biostudies-literature
ProteomicsHuma Multiple Myeloma Cell line, AMO1, treated with NCP26, LC-MSMS analysis
The human multiple myeloma cell line, AMO1, was treated with NCP26, an ATP-competitive EPRS inhibitor, and a total proteome-wide analysis was performed to determine the effect of NCP26 treatment on protein dynamics.
ORGANISM(S): Homo sapiens (Human) 
2023-03-11 | PXD029453 | Pride
Lc-msms Huma Ncp26 Multiple myeloma Cell line Tmt-labeling Amo1 
UnknownDeciphering the chronology of copy number alterations in Multiple Myeloma.
Not available
S-EPMC6435669 | biostudies-literature
UnknownSelective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy.
Not available
S-EPMC6728221 | biostudies-literature
UnknownClinical and genetic studies of thiamine metabolism dysfunction syndrome-4: case series and review of the literature.
Not available
S-EPMC9188987 | biostudies-literature
UnknownIn-depth analysis of alternative splicing landscape in multiple myeloma and potential role of dysregulated splicing factors.
Not available
S-EPMC9763261 | biostudies-literature
UnknownGenome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group.
Not available
S-EPMC7499613 | biostudies-literature
UnknownMUC1-C activates EZH2 expression and function in human cancer cells.
Not available
S-EPMC5547076 | biostudies-literature
UnknownBiallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma.
Not available
S-EPMC7870932 | biostudies-literature
Sort   by:  
 Page size